Capivasertib (AKT inhibitor) plus Fulvestrant Improves Survival in Aromatase Inhibitor Resistant, ER+/HER2- Advanced Breast Cancer
16474
post-template-default,single,single-post,postid-16474,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Capivasertib (AKT inhibitor) plus Fulvestrant Improves Survival in Aromatase Inhibitor Resistant, ER+/HER2- Advanced Breast Cancer

Home > Blogs  > Capivasertib (AKT inhibitor) plus Fulvestrant Improves Survival in Aromatase Inhibitor Resistant, ER+/HER2- Advanced Breast Cancer

18 Jun Capivasertib (AKT inhibitor) plus Fulvestrant Improves Survival in Aromatase Inhibitor Resistant, ER+/HER2- Advanced Breast Cancer

Posted at 10:30h in Blogs by

The addition of capivasertib to fulvestrant showed a significant PFS benefit in the original pathway-altered and non-altered subgroups. In the pathway altered subgroup, the median OS with the combination was significantly longer than fulvestrant alone. The expanded biomarker testing suggested that capivasertib predominantly benefits patients with PI3K/AKT/PTEN pathway-altered tumours. (Ref: Howell SJ et al.  Lancet Oncol. June 1, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6943811898039484416

No Comments

Sorry, the comment form is closed at this time.